- CEO
- Rossano Marques Leandro
- Full Time Employees
- 17,000
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Avenida das Américas, 4.200 Rio de Janeiro RJ Brazil 22640-907
- IPO Date
- Jul 26, 2007
- Business
- Yduqs Participações S.A. provides higher education services in Brazil, focusing on post-secondary programs through face-to-face, semi-face-to-face, and distance learning modalities; offers undergraduate, graduate, master's, and doctorate courses across legal, management, humanities, health, and technology areas; and operates edtech platforms including HardWork Medicina for medical exam preparation and Grupo Q with Qconcursos solutions for competitions. The company delivers these services under key brands such as Estácio for broad undergraduate offerings, UniToledo, Adtalem encompassing Ibmec for premium business education, Wyden, Damasio Educacional, SJT Med, Clio, IDOMED for medical programs, and Idomed; maintains a network of universities, campuses, distance learning centers, and colleges primarily in Brazil with nationwide operations. Founded in 1970 and headquartered in Rio de Janeiro at Avenida Venezuela 43, the company, formerly known as Estácio Participações S.A. until its rebranding in 2019, employs approximately 16,000 people and targets diverse student segments including on-campus undergraduates, premium business learners, and medical school candidates. In recent developments, Yduqs completed the acquisition of Faculdade Edufor in São Luís, Maranhão, in December 2024 for R$145 million, adding 118 medical school seats and 2,800 undergraduates primarily in law and health courses to bolster IDOMED and Estácio brands; integrated Centro Universitário Newton Paiva in Belo Horizonte in November 2024; and acquired Centro Universitário Unifametro involving over 8,000 students and potential medical openings, reflecting a strategy of targeted medical and on-campus expansions expected to enhance results from 2026 while supporting deleveraging. The company reported strong Q3 2025 performance with 4% net revenue growth to R$1.368 billion driven by premium segments like Ibmec (23% revenue increase), improved EBITDA margins, and trailing twelve-month free cash flow to equity of R$610 million exceeding guidance, alongside a net debt to EBITDA ratio reduction to 1.52x and premium revenue share rising to 31%.